

CombiGene: University of Copenhagen has become new shareholder

Following a share transfer from CombiGene's co-founder David Woldbye, the University of Copenhagen is now a shareholder in CombiGene, with 1.9% of the shares. The transaction is based on a mutual agreement from 2007.

The University of Copenhagen has become a shareholder in CombiGene and now holds 216 000 shares. The transfer fulfils an agreement dating back to a PCT patent application from 2007, which stipulated that the transfer would be conducted once CombiGene became a public and listed company.

"We are proud to have the distinguished University of Copenhagen as a shareholder", says CombiGene's Chairman Arne Ferstad and continues "It also reflects the value in the ongoing Swedish-Danish collaboration".

After the transaction was executed on January 12th 2016, University of Copenhagen owns 1.9% of the shares in CombiGene and David Woldbye owns 1.9%.

About University of Copenhagen

The University of Copenhagen is the largest university in Denmark and recognised as one of Europe's leading universities. Six faculties and the Biotech Research and Innovation Centre (BRIC) constitute the backbone of the University and the intellectual playground for 5,500 researchers and 40,000 students. The University of Copenhagen is ranked no 7 in Europe on the Leiden Ranking 2015 and is on the Top 50 list of institutions publishing articles in Nature and Science journals. www.ku.dk

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com

For further information:

CombiGene AB (publ)
Bengt Westrin, CEO
Tel: +46 70 - 265 48 62
email: bengt.westrin@combigene.com

Please read MORE FROM THE COMPANY, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and press releases are available at www.combigene.com

www.combigene.com

CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com